ArticleArthritis and rheumatism2006
Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.
Article in Arthritis and rheumatism, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 73 citations in OpenAlex.
- Lower NK cell numbers in children with untreated juvenile dermatomyositis during the COVID-19 pandemic.Clinical immunology communications · 2023Article
- Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.Rheumatology (Oxford, England) · 2023Article
- Low copy numbers of complementAnnals of the rheumatic diseases · 2023Article
- Juvenile Dermatomyositis.Journal of rheumatic diseases · 2022Review
- Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning.BMC endocrine disorders · 2021Observational
- Prevalence of Epstein-Barr virus infection and characteristics of lymphocyte subsets in newly onset juvenile dermatomyositis.World journal of pediatrics : WJP · 2021Article
- Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.Autoimmunity reviews · 2020Review
- Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.Annals of the rheumatic diseases · 2018Article
- Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.Arthritis care & research · 2017Article
- Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.Clinical reviews in allergy & immunology · 2017Review
- Beyond the MHC: A canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci.PLoS genetics · 2017Article
- Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Current opinion in rheumatology · 2014Review
- Article
- Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study.Annals of the rheumatic diseases · 2012Article
- Juvenile dermatomyositis: new insights and new treatment strategies.Therapeutic advances in musculoskeletal disease · 2012Article
- Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.Nature reviews. Rheumatology · 2011Review
- Juvenile dermatomyositis.Current rheumatology reports · 2011Review
- Recent advances in the immunogenetics of idiopathic inflammatory myopathy.Arthritis research & therapy · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo define the relative importance (RI) of class II major histocompatibility complex (MHC) alleles and peptide binding motifs as risk or protective factors for juvenile dermatomyositis (DM), and to compare these with HLA associations in adult DM.
methodsDRB1 and DQA1 typing was performed in 142 Caucasian patients with juvenile DM, and the results were compared with HLA typing data from 193 patients with adult DM and 797 race-matched controls. Random Forests classification and multiple logistic regression were used to assess the RI of the HLA associations.
resultsThe HLA-DRB1*0301 allele was a primary risk factor (odds ratio [OR] 3.9), while DQA1*0301 (OR 2.8), DQA1*0501 (OR 2.1), and homozygosity for DQA1*0501 (OR 3.2) were additional risk factors for juvenile DM. These risk factors were not present in patients with adult DM without defined autoantibodies. DQA1 alleles *0201 (OR 0.37), *0101 (OR 0.38), and *0102 (OR 0.51) were identified as novel protective factors for juvenile DM, the latter 2 also being protective factors in adult DM. The peptide binding motif DRB1 (9)EYSTS(13) was a risk factor, and DQA1 motifs F(25), S(26), and (45)(V/A)W(R/K)(47) were protective. Random Forests classification analysis revealed that among the identified risk factors for juvenile DM, DRB1*0301 had a higher RI (100%) than DQA1*0301 (RI 57%), DQA1*0501 (RI 42%), or the peptide binding motifs. In a logistic regression model, DRB1*0301 and DQA1*0201 were the strongest risk and protective factors, respectively, for juvenile DM.
conclusionDRB1*0301 is ranked higher in RI than DQA1*0501 as a risk factor for juvenile DM. DQA1*0301 is a newly identified HLA risk factor for juvenile DM, while 3 of the DQA1 alleles studied are newly identified protective factors for juvenile DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.